TY - JOUR
T1 - Research Communication
T2 - Breath Testing for Colorectal Cancer Detection in Patients With a Positive Fecal Immunochemical Test: A Multicentre Prospective Cross-Sectional Study With External Validation
AU - van Riswijk, Milou L.M.
AU - van Keulen, Kelly E.
AU - the eNose CRC study group
AU - Tan, Adriaan C.I.T.L.
AU - Schrauwen, Ruud W.
AU - de Vos tot Nederveen Cappel, Wouter H.
AU - Siersema, Peter D.
AU - van Riswijk, Milou L.M.
AU - van Keulen, Kelly E.
AU - Schrauwen, Ruud W.
AU - de Vos tot Nederveen Cappel, Wouter H.
AU - Siersema, Peter D.
AU - Jansen, J. M.
AU - Verhagen, Marc A.M.T.
AU - Spaander, Manon C.W.
AU - Wiegerinck, M.
AU - Derks, Monica E.W.
AU - Huang, Hui Jun
AU - Visserman, Renee
AU - Tenschert, Demi
AU - Klerks, Jip
AU - Hanevelt, Julia
AU - van der Velden, Kim
AU - Dooijes, Meike
AU - Welbergen, Geanne
AU - Straathof, J. W.A.
N1 - Publisher Copyright:
© 2025 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
PY - 2025/7
Y1 - 2025/7
N2 - Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) is suboptimal. This multicentre study evaluated an electronic nose (e-nose) for CRC detection in FIT-positive patients, along with reproducibility and external validation. Among 3469 participants (40.1% female, median age 64.3y), CRC was diagnosed in 5.0%; 25.1% had a normal colonoscopy. The e-nose showed poor diagnostic performance (AUC 0.542; sensitivity 39.5%; specificity 68.3%) and low reproducibility (ICC 0.22). Despite high patient acceptability (95.3% willingness-to-repeat), these findings suggest e-nose technology is not yet ready for clinical implementation. Further research is needed to standardise and validate e-nose devices before supplementing current screening methods. Clinicaltrials.gov Identifier NCT03346005 and NCT04357158.
AB - Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) is suboptimal. This multicentre study evaluated an electronic nose (e-nose) for CRC detection in FIT-positive patients, along with reproducibility and external validation. Among 3469 participants (40.1% female, median age 64.3y), CRC was diagnosed in 5.0%; 25.1% had a normal colonoscopy. The e-nose showed poor diagnostic performance (AUC 0.542; sensitivity 39.5%; specificity 68.3%) and low reproducibility (ICC 0.22). Despite high patient acceptability (95.3% willingness-to-repeat), these findings suggest e-nose technology is not yet ready for clinical implementation. Further research is needed to standardise and validate e-nose devices before supplementing current screening methods. Clinicaltrials.gov Identifier NCT03346005 and NCT04357158.
UR - https://www.scopus.com/pages/publications/105007779744
U2 - 10.1111/apt.70207
DO - 10.1111/apt.70207
M3 - Article
C2 - 40459533
AN - SCOPUS:105007779744
SN - 0269-2813
VL - 62
SP - 208
EP - 213
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 2
ER -
